Epigenetic dysregulation is increasingly appreciated as a hallmark of cancer, including
disease initiation, maintenance and therapy resistance. As a result, there have been …

Most patients with acute myeloid leukemia (AML) develop refractory/relapsed (R/R) disease
even in the presence of novel and targeted therapies. Given the biological complexity of the …

Chromatin-binding proteins are critical regulators of cell state in haematopoiesis,. Acute
leukaemias driven by rearrangement of the mixed lineage leukaemia 1 gene (KMT2A r) or …

Recent studies on pediatric acute myeloid leukemia (pAML) have revealed pediatric-specific
driver alterations, many of which are underrepresented in the current classification schemas …

PURPOSE Revumenib, an oral, small molecule inhibitor of the menin-lysine
methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a phase …

Balanced rearrangements involving the KMT2A gene (KMT2A r) are recurrent genetic
abnormalities in acute myeloid leukemia (AML), but there is lack of consensus regarding the …

Summary Background Ziftomenib (KO-539) is an oral selective menin inhibitor with known
preclinical activity in menin-dependent acute myeloid leukaemia models. The primary …

As epigenetic therapies continue to gain ground as potential treatment strategies for cancer
and other diseases, compounds that target histone lysine methylation and the enzyme …

Chromatin regulation involves the selective recruitment of chromatin factors to facilitate DNA
repair, replication and transcription. Here we demonstrate the utility of coupling unbiased …

The understanding of the molecular pathobiology of acute myeloid leukemia (AML) has
spurred the identification of therapeutic targets and the development of corresponding novel …